NEOMED-LABS Revenue and Competitors
Estimated Revenue & Valuation
- NEOMED-LABS's estimated annual revenue is currently $2M per year.
- NEOMED-LABS's estimated revenue per employee is $155,000
Employee Data
- NEOMED-LABS has 13 Employees.
- NEOMED-LABS grew their employee count by 0% last year.
NEOMED-LABS's People
Name | Title | Email/Phone |
---|
NEOMED-LABS Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $25.9M | 181 | 3% | $150.5M | N/A |
#2 | $28.4M | 183 | -56% | N/A | N/A |
#3 | $4.3M | 28 | 8% | N/A | N/A |
#4 | $55.6M | 359 | 1% | N/A | N/A |
#5 | $11M | 71 | 20% | N/A | N/A |
#6 | $22.2M | 143 | -22% | N/A | N/A |
#7 | $4.2M | 27 | 13% | N/A | N/A |
#8 | $2M | 13 | 0% | N/A | N/A |
#9 | $295.7M | 1908 | 5% | N/A | N/A |
#10 | $2.8M | 18 | 6% | N/A | N/A |
What Is NEOMED-LABS?
OVERVIEW NEOMED-LABS is a leading, independent, pure player in the immunology field whose team of experts and state of the art BSL2 labs were instrumental in the development, qualification, and validation of more than 30 assays supporting the FDA filing of 10 marketed vaccines with cumulative sales around $3bn. CAPABILITIES Protein sciences (immunotools), assay stability monitoring, high-throughput clinical testing (up to 200,000 results per year), automated readers, BSL2 bio-containment, samples storage capacity of over 500,000 samples on site (-20° to -80°), quality management systems and GCLP certified (Qualogy Inc.).
keywords:N/AN/A
Total Funding
13
Number of Employees
$2M
Revenue (est)
0%
Employee Growth %
N/A
Valuation
N/A
Accelerator
NEOMED-LABS News
The FDA hasn't ruled on products from Juul Labs, which controls 42% of the ... NEOMED Health Care is located on the second floor of the NEW...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $2.6M | 16 | -6% | N/A |
#2 | $2.2M | 18 | 0% | N/A |
#3 | $1.6M | 20 | -31% | $54.9M |
#4 | $2.8M | 20 | 18% | N/A |
#5 | $4.5M | 20 | 5% | N/A |